Description
Eriocalyxin B, isolated from the herbs of Isodon eriocalyx, is a potent NF-kappaB inhibitor. Eriocalyxin B inhibited the NF-kappaB transcriptional activity but not that of cAMP response element-binding protein. eriocalyxin B reversibly interfered with the binding of p65 and p50 subunits to the DNA in a noncompetitive manner. Eriocalyxin B exerts potent antiinflammatory effects through selective modulation of pathogenic Th1 and Th17 cells by targeting critical signaling pathways. Besides, Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways. Eriocalyxin B should be considered a candidate for pancreatic cancer treatment.